Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Imugene Ltd receives $6.5M R&D Tax Offset Refund

The company has noted that the funds will support its commercial and clinical milestones, several of which have progressed in recent months, including:

  • Granting of additional patents for the company’s HER-Vaxx Immunotherapy in China and South Korea;
  • Completion of Phase 1a trial of immunotherapy PD1-Vaxx;
  • US Food and Drug Administration (FDA) consent for clinical trials for its oncology treatments.

In recent years the market capitalisation of Imugene Ltd has increased significantly to over $2 Billion AUD.

To see if your company is eligible for the R&D Tax Offset, fill out our eligibility form here.



This post first appeared on Swanson Reed’s, please read the originial post: here

Share the post

Imugene Ltd receives $6.5M R&D Tax Offset Refund

×

Subscribe to Swanson Reed’s

Get updates delivered right to your inbox!

Thank you for your subscription

×